Richard J. O’reilly

Richard J. O’reilly's AcademicInfluence.com Rankings

Richard J. O’reilly

Philosophy

#5918

World Rank

#8853

Historical Rank

Logic

#3126

World Rank

#4240

Historical Rank

philosophy Degrees

Richard J. O’reilly

Biology

#7993

World Rank

#10999

Historical Rank

Immunology

#438

World Rank

#455

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Richard J. O’reilly's Degrees

Doctorate Medicine Columbia University

Why Is Richard J. O’reilly Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard J. O’reilly's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. (2005) (490)
Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. (1983) (481)
Killer Ig-Like Receptor Haplotype Analysis by Gene Content: Evidence for Genomic Diversity with a Minimum of Six Basic Framework Haplotypes, Each with Multiple Subsets1 (2002) (391)
Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates (1987) (390)
TRANSPLANTATION FOR ACUTE LEUKAEMIA WITH HLA-A AND B NONIDENTICAL PARENTAL MARROW CELLS FRACTIONATED WITH SOYBEAN AGGLUTININ AND SHEEP RED BLOOD CELLS (1981) (367)
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. (2012) (366)
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation : Effect of patient age and donor leukocyte infusions (1999) (351)
Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. (1986) (343)
Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma 1 (2003) (329)
Transplantation outcomes for severe combined immunodeficiency, 2000-2009. (2014) (326)
Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. (1990) (318)
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. (2007) (265)
Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. (2014) (263)
Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. (1987) (260)
Identification by HLA typing of intrauterine-derived maternal T cells in four patients with severe combined immunodeficiency. (1982) (228)
Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. (1987) (226)
Allogenic bone marrow transplantation: current status and future directions. (1983) (218)
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes (2003) (217)
TLR1 and TLR6 Polymorphisms Are Associated with Susceptibility to Invasive Aspergillosis after Allogeneic Stem Cell Transplantation (2005) (215)
T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. (1998) (212)
The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. (1996) (203)
Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts (1989) (202)
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. (1999) (201)
Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. (2010) (197)
Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. (1994) (183)
Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. (2002) (182)
Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts (1997) (179)
Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. (2017) (171)
B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. (1990) (163)
Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. (1977) (161)
Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. (1984) (157)
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. (2000) (156)
Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. (1990) (150)
Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody (2013) (149)
Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. (1983) (149)
Antileukemia activity of a natural killer cell line against human leukemias. (1998) (148)
Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. (1997) (140)
Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. (2012) (138)
Hyperfractionated total body irradiation for bone marrow transplantation: I. Early results in leukemia patients. (1981) (137)
Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections (2016) (129)
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. (2011) (128)
Invasive adenoviral infections in T‐cell‐depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir (2007) (128)
Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. (2009) (127)
The use of HLA-non-identical T-cell-depleted marrow transplants for correction of severe combined immunodeficiency disease. (1989) (126)
KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma (2009) (121)
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1 (2015) (120)
Allogeneic bone marrow transplantation for patients with acute lymphoblastic leukemia. (1983) (118)
Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. (1992) (117)
SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. (2018) (115)
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. (2015) (114)
Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. (2000) (114)
N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. (2001) (114)
Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. (1981) (110)
Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. (2009) (110)
Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL. (2019) (109)
ALLOGENEIC BONE MARROW TRANSPLANTATION USING STEM CELLS FRACTIONATED BY LECTINS: VI, IN VITRO ANALYSIS OF HUMAN AND MONKEY BONE MARROW CELLS FRACTIONATED BY SHEEP RED BLOOD CELLS AND SOYBEAN AGGLUTININ (1980) (107)
The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901 (2013) (105)
T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. (2007) (105)
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. (2015) (104)
Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV- induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice [published erratum appears in J Exp Med 1996 Sep 1;184(3):1199] (1996) (102)
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias (2003) (102)
Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation. (1990) (101)
M241 (CD1) expression on B lymphocytes. (1987) (101)
Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ hybridization. (1992) (101)
Marrow transplantation for juvenile osteopetrosis. (1981) (100)
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplant. (2020) (99)
Marrow transplantation for congenital disorders. (1984) (98)
Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. (2004) (96)
Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? (1995) (90)
Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. (1989) (89)
Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. (1984) (89)
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. (2011) (88)
Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. (1991) (87)
Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms. (1989) (87)
Cell-mediated immune responses in patients with recurrent Herpes Simplex infections. II. Infection-associated deficiency of lymphokine production in patients with recurrent herpes labialis or herpes progenitalis. (1977) (82)
Effects of in vitro purging with 4-hydroperoxycyclophosphamide on the hematopoietic and microenvironmental elements of human bone marrow. (1985) (82)
Effects of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model. (1989) (82)
Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan. (2005) (81)
Host origin of the human hematopoietic microenvironment following allogeneic bone marrow transplantation. (1987) (80)
High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates. (1990) (80)
Fludarabine‐based cytoreductive regimen and T‐cell‐depleted grafts from alternative donors for the treatment of high‐risk patients with Fanconi anaemia (2008) (80)
Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. (2004) (78)
Cell-mediated immune responses in recurrent herpesvirus infections. I. Lymphocyte proliferation assay. (1977) (77)
Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia. (2015) (76)
Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. (2011) (76)
Absence of interleukin 2 production in a severe combined immunodeficiency disease syndrome with T cells (1990) (76)
Purification and partial characterization of a human hematopoietic precursor population. (1991) (75)
Leukemia relapse in donor cells after allogeneic bone-marrow transplantation. (1981) (73)
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. (2008) (73)
T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. (2011) (73)
Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. (2008) (72)
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential (2015) (71)
Effects of recombinant human granulocyte-colony stimulating factor on hematopoietic reconstitution after autologous bone marrow transplantation in primates. (1987) (71)
High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. (1998) (70)
Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. (1999) (70)
ABH incompatible bone marrow transplantation: removal of erythrocytes by starch sedimentation (1983) (69)
ASSOCIATION BETWEEN PRE-TRANSPLANT NATURAL KILL AND GRAFT-VERSUS-HOST DISEASE AFTER STEM-CELL TRANSPLANTATION (1979) (69)
Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease (2007) (68)
In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. (2007) (68)
Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. (2006) (67)
Rapid selection of antigen-specific T lymphocytes by retroviral transduction. (2000) (67)
LEVAMISOLE AND INOSIPLEX: ANTIVIRAL AGENTS WITH IMMUNOPOTENTIATING ACTION * (1977) (66)
Circulating thymic hormone activity in patients with primary and secondary immunodeficiency diseases. (1981) (66)
Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. (2002) (65)
Ontogeny of lymphocyte subpopulations in human fetal liver. (1976) (64)
Primary Immune Deficiency Treatment Consortium (PIDTC) report. (2014) (64)
QUANTITATION OF T LYMPHOCYTES IN HUMAN BONE MARROW BY A LIMITING DILUTION ASSAY (1985) (61)
Direct evidence for new T-cell generation by patients after either T-cell–depleted or unmodified allogeneic hematopoietic stem cell transplantationsPresented in part in abstract form at the 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, December 2000. (2002) (61)
Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. (2012) (60)
WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. (2013) (60)
T-lymphocyte reconstitution in recipients of bone marrow transplants with and without GVHD: imbalances of T-cell subpopulations having unique regulatory and cognitive functions (1982) (60)
Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide (1981) (59)
Total body irradiation for bone marrow transplantation: the Memorial Sloan-Kettering Cancer Center experience. (1990) (58)
Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. (2012) (58)
DR‐POSITIVE MATERNAL ENGRAFTED T CELLS IN A SEVERE COMBINED IMMUNODEFICIENCY PATIENT WITHOUT GRAFT‐VERSUS-HOST DISEASE (1980) (58)
T-lymphocyte reconstitution in recipients of bone marrow transplants with and without GVHD: imbalances of T-cell subpopulations having unique regulatory and cognitive functions. (1982) (57)
Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation12 (2003) (57)
Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). (2008) (57)
Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation (2007) (56)
Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates. (1990) (56)
Marrow transplantation from human leukocyte antigen-identical or haploidentical donors for correction of Wiskott-Aldrich syndrome. (1991) (55)
Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin. (1988) (55)
Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice. (2004) (54)
Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. (1992) (54)
Immunology of Human Infection (1982) (54)
Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. (2012) (54)
Evaluation of HLA‐Haplotype Disparate Parental Marrow Grafts Depleted of T Lymphocytes by Differential Agglutination with a Soybean Lectin and E‐Rosette Depletion for the Treatment of Severe Combined Immunodeficiency 1 (1986) (54)
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. (2017) (53)
Effect of human exogenous leukocyte interferon in cytomegalovirus infections. (1976) (53)
Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3. (1993) (52)
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study (2018) (51)
In vitro correlates of graft-host tolerance after HLA-matched and mismatched marrow transplants: suggestions from limiting dilution analysis. (1987) (51)
Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high‐dose chemotherapy plus granulocyte‐macrophage colony‐stimulating factor a randomized trial (1993) (49)
An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment. (2010) (49)
Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. (1995) (48)
In vitro Stimulation with WT1 Peptide-Loaded Epstein-Barr Virus-Positive B Cells Elicits High Frequencies of WT1 Peptide-Specific T Cells with In vitro and In vivo Tumoricidal Activity (2004) (48)
Thymic activity in severe combined immunodeficiency diseases. (1977) (48)
Effect of stem cell factor on in vitro erythropoiesis in patients with bone marrow failure syndromes. (1992) (48)
Recombinant human granulocyte-colony stimulating factor: in vitro and in vivo effects on myelopoiesis. (1987) (47)
Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant (2017) (47)
Dose‐intensive use of cyclophosphamide in ablation of neuroblastoma (1990) (47)
CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. (2015) (47)
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors (2021) (47)
Successful treatment of human herpesvirus 6 encephalitis in a bone marrow transplant recipient. (1998) (46)
Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants (2007) (46)
A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity. (2014) (46)
Predictors for persistent cytomegalovirus reactivation after T‐cell‐depleted allogeneic hematopoietic stem cell transplantation (2007) (45)
Enrichment for CFU-C from murine and human bone marrow using soybean agglutinin. (1982) (45)
T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads. (1989) (45)
DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. (1999) (44)
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. (2013) (44)
Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. (2007) (44)
Papovavirus excretion following marrow transplantation: incidence and association with hepatic dysfunction. (1981) (44)
Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. (1996) (44)
Chronic mucocutaneous candidiasis with macrophage dysfunction, a plasma inhibitor, and co-existent aplastic anemia. (1975) (43)
Rationale for combined use of fetal liver and thymus for immunological reconstitution in patients with variants of severe combined immunodeficiency. (1977) (43)
Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin. (2014) (42)
In vitro interferon‐gamma production by cultured T‐cells in severe aplastic anaemia: correlation with granulomonopoietic inhibition in patients who respond to anti‐thymocyte globulin (1988) (42)
Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein (2014) (42)
Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. (2004) (41)
Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors (2016) (39)
A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. (2014) (39)
Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine‐based cytoreductive regimen and T‐cell‐depleted related HLA‐mismatched peripheral blood stem cell grafts (2000) (38)
Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide. (1981) (38)
[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity (2006) (38)
Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. (2017) (37)
Ten‐year follow‐up of pediatric patients with non‐hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation (2013) (37)
High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. (2015) (36)
Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts (2004) (36)
Effect of procarbazine and cyclophosphamide on chromosome breakage in Fanconi anemia cells: relevance to bone marrow transplantation. (1983) (35)
Bone marrow transplantation for thalassemia. The USA experience. (1994) (35)
Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts (2015) (35)
Nephropathy in the Wiskott-Aldrich syndrome. (1980) (34)
Use of humanized severe combined immunodeficient mice for human vaccine development (2009) (34)
Heterogeneity of stem cells in severe combined immunodeficiency. (1976) (34)
Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. (2010) (34)
Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. (1995) (33)
Lung transplantation after allogeneic marrow transplantation in pediatric patients: the Memorial Sloan-Kettering experience. (2001) (33)
Umbilical cord blood infusion in a patient for correction of Wiskott-Aldrich syndrome. (1994) (33)
Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant (2015) (32)
The probability of HLA-C matching between patient and unrelated donor at the molecular level: estimations based on the linkage disequilibrium between DNA typed HLA-B and HLA-C alleles. (1999) (31)
Paroxysmal nocturnal hemoglobinuria in pediatric patients (2012) (31)
Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses. (2016) (31)
Use of HLA genotypically different donors in bone marrow transplantation. (1979) (31)
Natural killer cell function and interferon generation in patients with primary immunodeficiencies. (1986) (31)
Bone Marrow Transplantation for Homozygous β‐Thalassemia: The Memorial Sloan‐Kettering Cancer Center Experience (1998) (30)
Joint transduction of separate extrachromosomal drug resistance determinants in Staphylococcus aureus E169. (1971) (30)
Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. (2007) (30)
HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease. (1987) (30)
Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. (2015) (30)
Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation. (1997) (29)
TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. (2018) (29)
ICAM-1 (CD54) expression on B lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7. (1994) (28)
B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. (2018) (28)
Characterization of B cells in severe combined immunodeficiency disease. (1989) (28)
A Panel of Artificial APCs Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Dominant and Subdominant Viral Epitopes for Adoptive Therapy1 (2009) (27)
Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature. (1986) (27)
Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT (2010) (27)
The use of T cell culture techniques to establish the presence of an intrauterine-derived maternal T cell graft in a patient with severe combined immunodeficiency (SCID). (1983) (27)
Effects of exogenous interferon in cytomegalovirus infections complicating bone marrow transplantation. (1976) (27)
Abnormal humoral immune responses in peripheral blood lymphocyte cultures of bone marrow transplant recipients. (1982) (26)
NCCN pediatric acute lymphoblastic leukemia practice guidelines. The National Comprehensive Cancer Network. (1996) (26)
Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to viral directed immunotherapy. (2020) (26)
Allogeneic Bone Marrow Transplantation : Current Status and Future Directions (2005) (26)
Transplantation of hematopoietic cells for lethal congenital immunodeficiencies. (1983) (25)
Association of reticular dysgenesis (thymic alymphoplasia and congenital aleukocytosis) with bilateral sensorineural deafness. (1999) (25)
CORRELATION OF CLINICAL AND VIRUS‐SPECIFIC IMMUNE RESPONSES FOLLOWING LEVAMISOLE THERAPY OF RECURRENT HERPES PROGENITALIS * (1977) (25)
Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted bone marrow transplantation: influence of conditioning and hematopoietic reconstitution. (1996) (24)
Specific antibody-blocking activities in antilymphocyte globulin as correlates of efficacy for the treatment of aplastic anemia. (1985) (23)
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies (2021) (23)
Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy (1989) (22)
Tolerance of engrafted donor T cells following bone marrow transplantation for severe combined immunodeficiency. (1988) (22)
Administration of rabbit anti-asialo GM1 antiserum facilitates the development of human Epstein-Barr virus-induced lymphoproliferations in xenografted C.B-17 scid/scid mice. (1996) (22)
Marrow transplantation for thrombocytopenia-absent radii syndrome. (1992) (22)
The diagnostic, prophylactic, and therapeutic uses of monoclonal antibodies to human cytomegalovirus. (1987) (21)
Bone marrow transplantation for acute non-lymphocytic leukemia: a report from the Childrens Cancer Study Group of sixty-seven children transplanted in first remission. (1987) (21)
NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. (1996) (21)
Lymphoma of host origin in a marrow transplant recipient in remission of acute myeloid leukemia and receiving cyclosporin A (1985) (20)
Clinical promise of new hematopoietic growth factors: M-CSF, IL-3, IL-6. (1989) (20)
Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. (2016) (20)
Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. (2000) (20)
Severe combined immunodeficiency: transplantation approaches for patients lacking an HLA genotypically identical sibling. (1978) (20)
Fusarium infections in patients with hematologic malignancies. (1990) (20)
Soybean Lectin Agglutination and E-Rosette Depletion for Removal of T-Cells from HLA-Identical Marrow Grafts: Results in 60 Consecutive Patients Transplanted for Hematologic Malignancy (1986) (19)
Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia. (2012) (19)
Selective IgA deficiency and circulating immune complexes containing bovine proteins in a child with chronic graft versus host disease. (1979) (19)
Histocompatibility testing for clinical bone marrow transplantation and prospects for identification of donors other than HLA genotypically identical siblings. (1980) (19)
Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion. (2015) (18)
Current Status of Treatment of Acute Leukemia in Adults: An Overview (1984) (18)
Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction (2019) (18)
High‐dose melphalan with 6‐hydroxydopamine–purged autologous bone marrow transplantation for poor‐risk neuroblastoma (1991) (18)
Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation. (2020) (18)
DISTRIBUTION OF HLA GENOTYPES IN FAMILIES OF PATIENTS WITH ACUTE LEUKEMIA: IMPLICATIONS FOR TRANSPLANTATION (1982) (17)
In vitro model for detection of alloreactivity between HLA-matched donor-host pairs. Preliminary evaluation as a predictor of graft-versus-host disease. (1982) (17)
DNA Methylation Enzymes and PRC1 Restrict B-cell Epstein-Barr Virus Oncoprotein Expression (2020) (17)
CD4+ T-cell reconstitution predicts Survival Outcomes after acute Graft-versus-Host-Disease; a dual center validation. (2020) (16)
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses. (2021) (16)
Circulating thymic hormone levels in severe combined immunodeficiency. (1983) (16)
T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells (2015) (16)
Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. (2018) (15)
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myeloid Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. (2020) (15)
Use of the Tetanus Toxoid, Reduced Dose Diphtheria and Pertussis Vaccine (Tdap) in Allogeneic Transplant (alloHCT) Recipients. (2008) (15)
Characterization of the in vitro sensitivity of human lymphoid and hematopoietic progenitors to L-leucyl-L-leucine methyl ester. (1991) (15)
Enhancement of T-lymphocyte differentiation in vitro by thymic extracts after bone marrow transplantation in severe combined immunodeficiencies. (1975) (15)
Chemotactic defects in severe combined immunodeficiency. (1978) (15)
Persistent cytomegalovirus infection: association with profound immunodeficiency and treatment with interferon. (1983) (15)
In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME) (2017) (15)
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. (2018) (14)
Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. (2021) (14)
Hematopoietic Cell Transplantation for Immunodeficiency Diseases (2009) (14)
Human herpesvirus 6B immediate‐early I protein contains functional HLA‐A*02, HLA‐A*03, and HLA‐B*07 class I restricted CD8+ T‐cell epitopes (2014) (14)
Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC (2018) (14)
HLA-C disparity between patients and unrelated donors matched for HLA-A, -B, and -DRB1 alleles: impact of serological vs. DNA typing for HLA-A and -B loci. (1999) (14)
Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation. (2018) (14)
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. (2019) (13)
Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. (2017) (13)
High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. (2020) (13)
Transplantation of HLA-mismatched marrow depleted of T-cells by lectin agglutination and E-rosette depletion. (1985) (13)
Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias (2009) (13)
Enrichment of peripheral blood stem cells in a primate model following administration of a single dose of rh-IL-1 beta. (1994) (13)
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. (2017) (13)
Leukocyte migration inhibitory factor (LMIF) profile in primary and secondary immunodeficiency disease. (1976) (12)
Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL (2015) (12)
IL-7 induces surface expression of B7/BB1 on pre-B cells and an associated increase in their costimulatory effects on T cell proliferation. (1994) (12)
T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies. (2017) (12)
Both ongoing suppression and clonal elimination contribute to graft-host tolerance after transplantation of HLA mismatched T cell-depleted marrow for severe combined immunodeficiency. (1990) (11)
Intrathymic injection of hematopoietic progenitor cells establishes functional T cell development in a mouse model of severe combined immunodeficiency (2017) (11)
New promise for autologous marrow transplants in leukemia. (1986) (11)
Durable Remission Following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies (2020) (11)
In vitro differentiation of human marrow T cell precursors by thymic factors in severe combined immunodeficiency. (1981) (11)
The AIS CELLector: a new technology for stem cell purification. (1992) (11)
Early intestinal microbial features are associated with CD4 T cell recovery after allogeneic hematopoietic transplant. (2022) (11)
Segregation of co-transduced streptomycin and tetracycline resistance in Staphylococcus aureus (1972) (10)
Double-Unit Cord Blood (CB) Transplantation Combined With Haplo-Identical CD34+ Cell-Selected PBSC Results In 100% CB Engraftment With Enhanced Myeloid Recovery (2013) (10)
Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us. (2011) (10)
Successful transplantation of marrow from an HLA-A, -B, -D mismatched heterozygous sibling donor into an HLA-D-homozygous patient with aplastic anemia. (1978) (10)
Intra-thymic/splenic engraftment of human T cells in HLA-DR1 transgenic NOD/scid mice. (2004) (10)
Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. (2018) (10)
Prevention of cytomegalovirus infection in bone marrow transplant recipients by prophylaxis with an intravenous, hyperimmune cytomegalovirus globulin. (1984) (10)
Recombinant human granulocyte-colony stimulating factor: in vivo effects on myelopoiesis in primates. (1988) (10)
Novel strategies for adoptive therapy following HLA disparate transplants. (2011) (10)
Optimal conditions for in vitro T cell depletion of human bone marrow by Campath-1a plus complement as demonstrated by limiting dilution analysis. (1989) (9)
Long-term prognosis for 1-year relapse-free survivors of CD34 cell–selected allogeneic hematopoietic stem cell transplantation: a landmark analysis (2017) (9)
Low Toxicity and Favorable Overall Survival in Relapsed/Refractory B-ALL following CAR T cells and CD34-selected T Cell Depleted Allogeneic Hematopoietic Cell Transplant. (2020) (9)
Antithoracic duct lymphocyte globulin [letter] (1983) (9)
Acquired CMV chorioretinitis in severe combined immunodeficiency. (1978) (9)
Failure of immunologic reconstitution in a patient with the DiGeorge syndrome after fetal thymus transplantation. (1979) (9)
Successful treatment of diamond‐blackfan anemia with interleukin 3 (1993) (9)
Relevance of major human histocompatibility determinants in clinical bone marrow transplantation. (1976) (9)
Antithoracic duct lymphocyte globulin. (1983) (9)
Stage IV neuroblastoma more than 1 year of age at diagnosis: major response to chemotherapy and survival durations correlated strongly with dose intensity. (1991) (9)
Reconstitution of immunologic function in a patient with severe combined immunodeficiency following transplantation of marrow from an HLA-A,B,C nonidentical but MLC-compatible paternal donor. (1979) (9)
T-cell depletion and allogeneic bone marrow transplantation. (1992) (9)
Alteration in lymphoid chimerism associated with cytomegalovirus infection after bone marrow transplantation. (1979) (8)
Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. (2016) (8)
Abstract CT107: Epstein-Barr virus-specific cytotoxic T lymphocytes for treatment of rituximab-refractory Epstein-Barr virus-associated lymphoproliferative disorder (2015) (8)
Engraftment Kinetics after Transplantation of Double Unit Cord Blood Grafts Combined with Haplo-identical CD34+ Cells without Anti-thymocyte Globulin (2020) (8)
Third Party Donor Derived CMV Specific T Cells for the Treatment of Refractory CMV Viremia and Disease after Hematopoietic Stem Cell Transplant (2014) (8)
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT (2021) (8)
Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder (2017) (8)
High pressure liquid chromatographic determination of cyclosporin-A in human plasma. (1982) (8)
T-cell-depleted hematopoietic SCT from unrelated donors for the treatment of congenital amegakaryocytic thrombocytopenia (2012) (8)
Characteristics of human EBV-specific cytotoxic T lymphocytes utilized for adoptive immunotherapy of EBV-induced lymphoproliferations in xenografted SCID mice. (1997) (8)
Ocular outcomes after treatment of cytomegalovirus (CMV) retinitis using adoptive immunotherapy with CMV-specific cytotoxic T-lymphocytes. (2021) (8)
SubsetsFramework Haplotypes, Each with Multiple Diversity with a Minimum of Six Basic by Gene Content: Evidence for Genomic Killer Ig-Like Receptor Haplotype Analysis (2002) (8)
The Role of Residual Host Immunity in Graft Failures following T‐cell‐depleted Marrow Transplants for Leukemia a (1987) (8)
Immunosuppression prior to marrow transplantation for sensitized aplastic anemia patients: comparison of TLI with TBI. (1988) (7)
CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT (2012) (7)
Bone marrow transplants in patients lacking an HLA-matched sibling donor. (1991) (7)
Cell-Mediated Immune Responses in Recurrent Herpesvirus Infections (1977) (7)
Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS (2016) (7)
Absence of demonstrable suppressor cell activity in a severe combined immunodeficiency patient with a sustained engraftment of DR-positive maternal T cells. (1981) (7)
Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104 (1997) (7)
Hyperfractionated total body irradiation for bone marrow transplantation: II. Physical aspects of the combined electron-photon treatment plan (1980) (7)
Epstein-Barr virus sustains tumor killers (2008) (7)
Characterizing Ionizing Radiation Exposure after T-Cell Depleted Allogeneic Hematopoietic Cell Transplantation (2017) (7)
Pre-salvage ISS and Other Important Outcome Associations in CD34 Selected Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma. (2020) (7)
Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34 Selected Grafts. (2021) (7)
Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies. (2009) (7)
Loss of tolerance associated with disappearance of B cells in a patient sequentially transplanted with paternal and maternal bone marrow for the treatment of severe combined immunodeficiency disease. (1989) (6)
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. (2017) (6)
190 T-cell depleted (SBA-E-) bone marrow transplantation for myelodysplastic syndromes (1997) (6)
Hematologic analysis of clinical bone marrow grafting evaluated by in vitro cultures. (1976) (6)
A novel HLA class II-independent TCR-mediated T cell activation mechanism is distinguished by the V beta specificity of the proliferating oligoclones and their capacity to generate interleukin-2. (1996) (6)
Immunodeficiency diseases — a review (1979) (6)
Cancer–Testis Antigen 7 Expression and Immune Responses Following Allogeneic Stem Cell Transplantation for Multiple Myeloma (2014) (6)
Outcomes Following Treatment for Adenosine Deaminase Deficient Severe Combined Immunodeficiency: A Report from the PIDTC. (2022) (6)
Adoptive T-Cell Therapy with 3rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant (2017) (6)
Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us. (2010) (6)
Autologous bone marrow transplant using 4-HC, VP-16 purged bone marrow for acute non-lymphoblastic leukemia. (1989) (6)
Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin. (1982) (6)
Bone marrow transplantation for the therapy of refractory adult T cell acute lymphoblastic leukemia (1980) (6)
Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. (2019) (6)
Cytotoxic and proliferative T-cell clones with antidonor reactivity from a patient transplanted for severe combined immunodeficiency disease. (1990) (5)
Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant (2016) (5)
The Hematopoietic Cell Transplant-Co-Morbidity Index (HCT-CI) Predicts Outcomes After T Cell Depleted (TCD) Allogeneic HCT For AML and MDS (2013) (5)
The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions. (2022) (5)
Phase II Trial of a Chemotherapy-Only Regimen of Busulfan, Melphalan, Fludarabine and R-ATG Followed by Allogeneic T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplants (HSCT) for the Treatment of Myeloid Malignancies. (2007) (5)
Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy (1997) (5)
Anomalous killer cells: thymus cell dependency, precursor frequency, and response to immunosuppressive therapy. (1982) (5)
Cytomegalovirus Reactivation Promotes CD8+ T Cell Subset Recovery after Unmodified Allogeneic Hematopoietic Cell Transplantation (2019) (5)
Language recovery following isolation for severe combined immunodeficiency disease (1983) (5)
Evidence that appearance of thymulin in plasma follows lymphoid chimerism and precedes development of immunity in patients with lethal combined immunodeficiency transplanted with T cell-depleted haploidentical marrow. (1990) (5)
Viruses and parasites : Immunodiagnosis and prevention of infectious diseases (1982) (5)
Banked EBV-specific T-cells from HLA-partially matched normal donors to induce durable remissions of rituximab refractory EBV+ B-cell lymphomas post hematopoietic and organ allografts. (2015) (5)
Disease-Free Survival After Cord Blood (CB) Transplantation Is Not Different to That After Related or Unrelated Donor Transplantation in Patients with Hematologic Malignancies. (2009) (5)
Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro. (1990) (4)
A comparative review of the results of transplants of fully allogeneic fetal liver and HLA-haplotype mismatched, T-cell depleted marrow in the treatment of severe combined immunodeficiency. (1985) (4)
Dissection of the function of HLA class II and costimulation in B cell-mediated and toxic shock syndrome toxin-1-induced T cell proliferation. (1993) (4)
Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation (2021) (4)
Enhancement of T lymphocyte differentiation in vitro by thymic extracts and purified polypeptides in severe combined immunodeficiency diseases. (1975) (4)
AML patients lacking kir ligand for donor KIR exhibit increased overall survival in HLA-identical sibling transplants (2004) (4)
Toxicities and Outcomes in the First Year after Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies (2017) (4)
The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions. (2022) (4)
Third Party Donor Derived EBV Specific T Cells for the Treatment of Refractory EBV-Related Post-Transplant Lymphomas (2014) (4)
Granulocyte colony-stimulating factor (CSF) but not interleukin-1 (IL-1), IL-3, and granulocyte-macrophage CSF protect bone marrow progenitor cells from suppression by allosensitized cytotoxic T cells. (1994) (4)
Bacteria, Mycoplasmae, Chlamydiae, and Fungi (1981) (4)
Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy (2022) (4)
Immunologic aspects of hematopoietic stem-cell transplantation. (2002) (4)
Erythropoiesis following bone marrow transplantation for thalassemia major. (1988) (4)
Late complications of mixed chimerism following allogeneic bone marrow transplantation for thalassemia major (2015) (4)
Vaccine Reponses Following Unmodified or T Cell Depleted Unrelated and Mismatched Related HCT. (2004) (4)
Early Hematopoietic Cell Transplant (HCT) Outcomes of Children with Severe Combined Immunodeficiency Disease (SCID): The First Seventy Four Patients of the Primary Immune Deficiency Treatment Consortium (PIDTC) Prospective Study 6901 (2015) (4)
Bone marrow transplantation in two multiply transfused patients with thalassaemia major (1986) (4)
Effects of hematopoietic growth factors following myeloablation in a primate model. (1990) (3)
Pilot Trial of Rituximab for the Prevention of Epstein Barr Virus B Cell Lymphoproliferative Disorder (EBV-LPD) Following T Cell Depleted (TCD) Unrelated or HLA-Mismatched Related Hematopoietic Stem Cell Transplantation. (2006) (3)
Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical Peripheral Blood CD34+ Cells (HaploCD34+) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection, and Frequent Pre-Engraftment Syndrome (2015) (3)
A Phase I Dose Escalation Trial of Donor T Cells Sensitized with Pentadecapeptides of the CMV-pp65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants. (2009) (3)
Double-Unit Cord Blood (CB) Transplantation Combined with Haplo-Identical CD34+ Cells Results in 100% CB Engraftment with Enhanced Myeloid Recovery (2014) (3)
Early CD4+ T Cell Reconstruction As Predictor for Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric and Young Adult Patients: A Validation Cohort Analyses (2020) (3)
Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL (2014) (3)
HLA-Identical Sibling-Matched, CD34+ Selected, T Cell Depleted Peripheral Blood Stem Cells Following Myeloablative Conditioning for First or Second Remission Acute Myeloid Leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303. (2009) (3)
Immunogenicity of the Tetravalent Protein-Conjugated Meningococcal Vaccine in Recipients of Related and Unrelated Allogeneic Hematopoietic Cell Transplants (HCT) (2008) (3)
Graft-Vs-Graft Immune Interaction Is the Likely Mechanism of Absolute Unit Dominance in Double Unit Cord Blood (DCB) Transplantation Using Patient DCB Grafts: An in Vivo but Not in Vitro Phenomenon (2008) (3)
Treatment of EBV+ nasopharyngeal carcinoma with banked EBV-specific cytotoxic T cells. (2016) (3)
Poor T Cell Reconstitution at 100 Days after T Cell-Replete Hematopoietic Cell Transplantation (HCT) for SCID Is Associated with Later Risk of Death or Need for 2nd Transplant in the 6901 Prospective Study of the Pidtc (2016) (3)
Abstract IA07: Chimeric antigen receptor T cells for cancer immunotherapy (2016) (3)
Immunogenicity of Haemophilus Influenza and Pneumococcal Vaccines in Related and Unrelated Transplant Recipients. (2006) (3)
Cell-Mediated Immune Responses in Patients with Recurrent Herpes Simplex Infections (1977) (3)
WT1-Specific Immune Responses in Patients with High-Risk Multiple Myeloma Undergoing Allogeneic T Cell-Depleted Hematopoietic Stem Cell Transplantation Followed by Donor Lymphocyte Infusions (2011) (3)
Double-Unit Cord Blood Transplantation (DCBT) for Acute Leukemia: High Disease-Free Survival in Adults and Children with Comparable Survival in European and Minority Patients (2011) (3)
Bone marrow transplantation for correction of severe aplastic anemia and primary immunodeficiency. (1981) (3)
A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models (2013) (3)
JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID) (2021) (3)
Clinical trials of hematopoietic cell transplantations: current needs and future strategies. (2000) (3)
Association of circulating immune complexes containing bovine proteins and graft-versus-host disease. (1986) (3)
Allogeneic stem cell transplantation (2004) (3)
Granulocyte colony-stimulating factor (CSF) but not interleukin-1 (IL- 1), IL-3, and granulocyte-macrophage CSF protect bone marrow progenitor cells from suppression by allosensitized cytotoxic T cells (1994) (3)
Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen–matched or –mismatched donors (2016) (3)
Conditioning Prior to CAR T Cells Predicts Response and Survival in Pediatric/Young Adult Relapse/Refractory (R/R) B-ALL (2019) (2)
In vitro purging with 4-hydroperoxycyclophosphamide and its effects on the hematopoietic and stromal elements of human bone marrow (1985) (2)
Detection of posttransplant minimal disease chronic myelogenous leukemia by bcr rearrangement analysis. (1989) (2)
Efficacy of Donor and ‘Third Party’ (Tabelecleucel) EBV-Specific T Cells for Treatment of Central Nervous System (CNS) EBV-PTLD (2019) (2)
Two Chemotherapy-Based Conditioning Regimens Compared To TBI-Based Conditioning Secure Consistent Engraftment Of T-Cell Depleted Allogeneic HSCT, Similarly Low Incidences Of Gvhd and Favorable Rates Of Disease-Free Survival (DFS) (2013) (2)
A TCR mimic monoclonal antibody reactive with the “public” phospho-neoantigen pIRS2/HLA-A*02:01 complex (2022) (2)
IL-15 Enhances in-vitro Expansion And Functional Activity Of Antigen-Specific Effector Memory T Cells (TEM) While Co-Expression Of IL-15 And IL-15 Rα On Antigen Presenting Cells Also Promotes Enrichment And Preferential Expansion Of Central Memory T-Cells (TCM) (2010) (2)
Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches (2015) (2)
Immunology of human infections. part II: viruses and parasites; immunodiagnosis and prevention of infectious diseases. (1982) (2)
T Cells Expressing Cars Directed Against HLA-0201 –Rmf WT-1 Peptide Complex Can Effectively Eradicate WT1+ A0201+ Tumor Cells in-Vitro (2014) (2)
Adoptive Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides of the CMV-pp65 Protein for the Treatment of Persistent CMV Antigenemia Following Allogeneic Hematopoietic Stem Cell Transplants (2012) (2)
Response to Immunizations Following Allogeneic HCT with Adjuvant Rituximab Therapy. (2005) (2)
USE OF GNOTOBIOTIC METHODS FOR A CHILD WITH SEVERE COMBINED IMMUNODEFICIENCY(SCID) TRANSPLANTED WITH MARROW FROM AN UNRELATED MIXED LYMPHOCYTE CULTURE (MLC) COMPATIBLE DONOR (1974) (2)
Adoptive Therapy with EBV-Specific T Cells for Treatment of CNS EBV Post-Transplant Lymphoproliferative Disease Arising after Hematopoietic Stem Cell Transplant or Solid Organ Transplant (2018) (2)
Reconstitution of in vitro humoral immune function in bone marrow transplant recipients. (1986) (2)
Dyshematopoiesis in combined immune deficiency with congenital neutropenia (1994) (2)
Leukemia-Reactive Cytotoxic CD8 + and CD4 + T-Cells Specific for Novel WT-1 Epitopes Are Generated In Vitro by Sensitization with Overlapping Pentadecapeptides (15-mers) Spanning the Wilms Tumor Protein. (2007) (2)
Early CD4+ T-Cell Reconstitution Is an Excellent Predictor for Survival and Non-Relapse Mortality in Pediatric and Young Adult Patients Who Develop Moderate to Severe Acute Graft-Versus-Host-Disease; A Dual Center Validation (2020) (2)
Robert Alan Good, MD, PhD. (2003) (2)
The Diagnosis, Prevention and Treatment of Human Cytomegalovirus Infections Using Human and Murine Monoclonal Antibodies (1988) (2)
Efficacy and safety of tabelecleucel in patients with EpsteinBarr Virus-associated leiomyosarcomas (EBV+ LMS) (2018) (2)
Bone marrow transplantation using typing for glyoxalase I as a tool in histocompatibility testing. (1979) (2)
Sensitization of Human T Cells with Overlapping Pentadecapeptides Spanning the Wt1 Protein Induces Expansion of Leukemocidal T Cells Specific for Both Previously Identified and Novel WT1 Epitopes. (2004) (2)
Adoptive Treatment Of EBV-Associated Leiomyosarcoma In Immunodeficient Patients With EBV Specific Cytotoxic T Cells (2013) (2)
Retroviral Vector‐mediated Gene Transfer and Expression in Nonhuman Primates Following Autologous Bone Marrow Transplantation a (1987) (2)
Genotype, Phenotype and T Cell Counts at One Year Predict Survival and Long Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency (SCID)—The Primary Immune Deficiency Treatment Consortium (PIDTC) (2017) (2)
High Disease-Free Survival and Enhanced Protection Against Relapse after Double-Unit Cord Blood Transplantation (DCB-T) When Compared to Unrelated Donor Transplantation (URD-T) in Patients with Acute Leukemia, MDS and CML (2014) (2)
Allelic polymorphisms of inhibitory killer immunoglobulin-like receptor natural killer cell function can also influence the graft-versus-leukemia response. (2013) (2)
A Panel of Artificial Antigen-Presenting Cells (AAPC) Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Subdominant and Dominant Viral Epitopes for Adoptive Therapy. (2007) (2)
Durable responses to 3rd party viral specific T cells mediated by different patterns of engraftment (2019) (2)
Immunogenicity of the Live Attenuated Varicella Vaccine Following Allogeneneic HCT. (2009) (2)
Durable engraftment and excellent overall survival after CD34-selected peripheral blood stem cell boost in pediatric patients with poor graft function following allogeneic stem cell transplantation. (2022) (2)
Banked, GMP Grade Third Party T-Cell Lines Specific for CMVpp65 Epitopes Presented By Certain Prevalent HLA Alleles More Consistently Clear CMV Infections in a Genetically Heterogeneous Population of HSCT Recipients (2014) (2)
Emerging Therapies for Chronic GVHD (2002) (2)
Bone marrow transplantation: current status. (1982) (2)
IL-15 Enhances in-vitro Expansion And Functional Activity Of Antigen-Specific Effector Memory T Cells (TEM) While Co-Expression Of IL-15 And IL-15 Rα On Antigen Presenting Cells Also Promotes Enrichment And Preferential Expansion Of Central Memory T-Cells (TCM) (2010) (2)
Generation and Characterization Of a Third Party GMP Grade Bank Of CMV Specific T-Cells For Adoptive Immunotherapy Of CMV Infections In Recipients Of HSCT From Cord Blood Or Seronegative Donors (2013) (2)
Targeting Wilms' Tumor 1 Protein Following CD34-Selected Allografts By Adoptive Transfer of Donor-Derived CTLs in Patients with Advanced Multiple Myeloma (2016) (1)
Outcomes In Patients With Acute Lymphoblastic Leukemia In First Or Second Complete Remission Receiving Ex-Vivo T-Cell Depleted Or Unmodified Allografts: Comparison Of Results At Two Institutions (2013) (1)
Human Norepinephrine Transporter Gene Human Antigen-Specific T Cells Transduced to Express a Imaging and Quantitation of Adoptively Transferred In vivo (2007) (1)
Virus Specific T-Lymphocytes Genetically Modified to Target the CD19 Antigen Eradicates Systemic Lymphoma In Mice (2010) (1)
T-Cell–Depleted Allogeneic Bone Marrow Transplant From HLA-Matched Sibling Donors for Non-Hodgkin’s Lymphoma (1999) (1)
A Panel of Artificial Antigen Presenting Cells (AAPC) Permits Immediate Sensitization and Rapid Generation of Virus-Specific T-Cells of Desired HLA Restriction for Adoptive Immunotherapy. (2006) (1)
Identification of novel WT1 epitopes by sensitization of human T cells with overlapping pentadecapeptides spanning the WT1 protein for the targeted adoptive immunotherapy of leukemia (2005) (1)
The Capacity of CMV-Specific T-Cells to Prevent Outgrowth of Clonogenic Human Colon Carcinoma Cells Co-Expressing CMVpp65 in-Vivo and Durably Suppress Established CMVpp65+ Tumor Xenografts Is Dose Dependant and Can Be Augmented by IL-15/IL-15Rα (2011) (1)
A Phase II Trial of Busulfan, Melphalan, and Fludarabine followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants from HLA-Identical, or HLA-Non Identical Related or Unrelated Donors for the Treatment of Advanced Hematopoietic Malignancies. (2004) (1)
CMV-Specific T-Cells Are More Effective Than WT-1-Specific T-Cells in Eradicating Clonogenic Tumor Cells Co-Expressing CMVpp65 and WT-1 in-Vivo and Both Types of T-Cells Are Functionally Augmented in the Presence of IL-15/IL-15Rα (2011) (1)
Baseline Immune Status As a Corollary to Response to Adoptive Therapy with CMV or EBV CTLs (2021) (1)
A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS (2012) (1)
Treatment of Cytomegalovirus (CMV) Retinitis with CMV-Specific T-Lymphocyte Infusion (2015) (1)
Addressing the envelope for gene delivery. (2012) (1)
Day 45 Lymphocyte Recovery Is Independently Associated with Transplant-Related Mortality after Adult Myeloablative Double-Unit Cord Blood Transplantation (dCBT) (2014) (1)
48 Sustained engraftment of HLA-matched related, T-cell depleted (TCD), peripheral blood stem cell (PBSC)/bone marrow (BM) transplants in adults with hematologic malignancies without the use of antithymocyte globulin (ATG) (2003) (1)
Immune-Mediated Hemolytic Anemia (IMHA) and Immune Thrombocytopenia (ITP) after Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation (2017) (1)
Post-Transplant Toxicities and Outcomes in Long-Term Survivors of Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation (2017) (1)
Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using “Low-dose” Cyclophosphamide, ATG Plus Fludarabine (2018) (1)
Stem Cell-Like Memory T-Cells (TSCM) are a Principal Source for Rapid Repopulation of Immunodominant CMVpp65 Specific Central Memory (TCM) and Effector Memory (TEM) T-Cells (2017) (1)
An Animal Model That Predicts Unit Engraftment in Double Unit Cord Blood Transplant Recipients. (2007) (1)
Effectson Hematopoiesis inNormal and Cyclophosphamide-treated Primates (1987) (1)
Adoptive Transfer Of WT-1 Specific HLA Class 2 Restricted Donor-Derived T-cells Induces Sustained Remission Of AML Relapse Post Transplant Presenting As Leukemia Cutis (2013) (1)
Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma (2017) (1)
High Dose Busulfan and Fludarabine with Anti-Thymocyte Globulin (ATG) Followed by Unmodified Marrow Grafts from HLA-Matched Siblings for the Treatment of High Risk Hemoglobinopathies (HGBpathies). (2005) (1)
Bone marrow transplantation for acute non-lymphocytic leukemia (1987) (1)
Clofarabine, Melphalan, and Thiotepa, Followed by Allogeneic Unmodified Bone Marrow or Peripheral Blood Stem Cell Transplant, by Unmodified Double Cord Blood Transplant, or by CD34+ T-Cell Depleted Stem Cell Transplant for the Treatment of Hematologic Malignancies. (2012) (1)
Early Fluid Overload is a Serious Toxicity Associated with an Increased Risk of Non-Relapse Mortality after Ex-Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation (2018) (1)
Non-Hodgkins lymphoma (1983) (1)
Graft Host Interactions Following T-Cell Depleted Marrow Transplants (1989) (1)
Artificial Antigen-Presenting Cells Permit Selective In Vitro Generation of CMV-Specific T-Cells of Desired HLA Allelic Restriction for Adoptive Immunotherapy in Recipients of HLA Disparate Allografts. (2005) (1)
Targeted Therapy of B Cell Lymphoma with a Direct Inhibitor of the NF-κB Subunit c-Rel (2014) (1)
Retrospective Study of 240 Patients with Severe Combined Immunodeficiency Transplanted from 2000-2009: A Report from the Primary Immune Deficiency Treatment Consortium of North America (2014) (1)
16 OUTCOMES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROME RECEIVING EX-VIVO T-CELL DEPLETED OR UNMODIFIED ALLOGRAFTS: COMPARISON OF RESULTS AT TWO INSTITUTIONS (2015) (1)
Factors Contributing to Viral Infections and the Limited Efficacy of Adoptively Transferred Donor Derived Immunodominant Virus-Specific T-Cells in Recipients of Haploidentical Stem Cell Transplants (2012) (1)
WT1-Specific T-Cell Responses Following T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation and Donor Lymphocyte Infusions in Patients with High-Risk Multiple Myeloma (2012) (1)
Generation of T Cells of Desired HLA Restriction Specific for Epitopes of a Self-Antigen, WT1, for the Adoptive Immunotherapy of WT1 Positive Malignancies Using A Panel of Artificial Antigen Presenting Cells Expressing Prevalent HLA Alleles. (2009) (1)
Engineered Antigen- Presenting Cells Expressing Human HLA Class-II DR Alleles Support Efficient Enrichment and Expansion of Antigen Specific Th1 CD4[+] T-Cells Which Are Functionally Augmented by IL-15Rα/IL-15 Complexes (2012) (1)
Third Party Donor Derived EBV Specific T Cells for the Treatment of Refractory EBV-Related Malignancies in Immunodeficient Recipients (2012) (1)
The Memorial Sloan-Kettering Experience With Allogeneic Stem Cell Transplantation For T Cell Non-Hodgkins Lymphomas (2010) (1)
Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on Close Haplo-Winning CB Unit HLA-Match (2018) (1)
Analysis of Cytomegalovirus (CMV) Infections in the First 180 Days in Adult Sero-Positive Cord Blood Transplantation (CBT) Recipients Reveals High Infection Rates and Treatment Burden (2018) (1)
Results of T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) from HLA Matched (HLA-M) or Partially Mismatched (HLA-MM) Unrelated Donors (URD) in Patients with Hematologic Malignancies: Sustained Engraftment and Low Incidence of Graft-vs-Host Disease (GvHD). (2006) (1)
Allogeneic Stem Cell Transplantation for Sickle Cell Anemia (SCA) at MSKCC: A Single Institution Series (2012) (1)
Wilms’ tumor 1 protein is highly expressed on malignant plasma cells and provides a novel target for immunotherapeutic approaches (2015) (1)
Fludarabine (Flu) Based Cytoreductive Regimen and T-Cell Depleted Grafts from Unrelated or Mismatched Related Donors for the Treatment of High Risk Patients with Fanconi Anemia (FA). (2004) (1)
Surgical implications of hepatic venocclusive disease following bone marrow transplantation (1988) (1)
Transplantation Outcomes for Children with Severe Combined Immune Deficiency (SCID) Have Improved over Time: A 36-Year Summary Report By the Primary Immune Deficiency Treatment Consortium (PIDTC) (2020) (1)
Colon Adenocarcinoma Class I Chain-Related Molecules Expressing Evasion from NK Cell Immunity by MHC and (2003) (1)
Correlation of Epstein-Barr virus-specific cytotoxic T lymphocyte precursors (EBV-CTLp) after tabelecleucel with response and survival in rituximab relapsing or refractory EBV+ post-transplant lymphoproliferative disease (PTLD). (2020) (1)
In Vivo Eradication of Human Clonigenic Acute Lymphoblastic Leukemic Cells Expressing the Wilms Tumor Protein, WT-1, by HLA Restricted WT-1 Specific T-Cells in NOD/SCID Mice Monitored by Bioluminescent Imaging. (2007) (1)
Phase I Trial of Prophylactic Rituximab for the Prevention of Post Transplant Epstein-Barr Related Lymphoproliferative Disease (EBV-PTLD) Following T Cell Depleted (TCD) Unrelated or HLA-Mismatched Related Hematopoietic Cell Transplantation (HCT): Efficacy, Toxicity, and Effect on Subsequent B Cell (2011) (1)
IL-15 Augments in-Vitro Expansion and Functional Activity of Antigen-Specific Effector Memory T-Cells (TEM) While Co-Expression of IL-15 and IL-15 Rα on Antigen Presenting Cells Also Promotes Expansion of Central Memory T-Cells (TCM) (2008) (1)
Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV+) Leiomyosarcomas (LMS) (2022) (1)
Adoptive Transfer Of EBV Specific T-Cells For Treatment Of Primary And Rituxan Resistant EBV Lymphomas Following Allogeneic Stem Cell Transplants (HSCT): Clinical, Viral And Immunologic Corelates (2010) (1)
Early Immune Recovery Predicts Overall and Disease-Free Survival After Allogeneic Hematopoietic Stem Cell Transplantation. (2009) (1)
Bone marrow transplantation in the treatment of leukemia. (1980) (1)
Mixed lymphocyte reactions for individuals with phenotypic identity for specific HLA-B, DR determinants: The role of linkage disequilibrium and of specific DR and other class II determinants (1983) (1)
Epitopes of CMVpp65 Co-Presented by Multiple Allelic Variants of HLA Class-I Antigens: Implications for Adoptive Immunotherapy for CMV Using Third Party Donor – Derived CMV Specific CTLs (2013) (1)
Long-Term Prognosis Among 1-Year Survivors of Ex Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis (2016) (1)
Third party CMV viral specific T-cells for refractory CMV viremia and disease after hematopoietic transplant. (2023) (1)
Effects of in vivo administration of human recombinant IL-2 to cynomolgus monkeys after autologous bone marrow transplantation. (1987) (1)
Allogeneic Hematopoietic Stem Cell Transplant with Ablative Conditioning Is Associated with Favorable Outcomes in Patients with Mixed Phenotype Acute Leukemia (2016) (1)
Growth Potential of Human Leukemia Blast Cells in SCID Mice and Association with Prognosis of Human Acute Leukemias. (2004) (0)
Bone Marrow Transplantation for Children with Acute Lymphoblastic Leukemia Failing Conventional Therapy (1994) (0)
Adoptively Transferred CMV-Specific T-Cells Responsive to Immunodominant CMVpp65 Epitopes Extend Durable in-Vivo Suppression of Clonogenic CMVpp65 [+] Human Colon Carcinoma Cells in Comparison to T-Cells Responsive to Subdominant Epitopes (2015) (0)
Successful Treatment of Refractory CMV Chorioretinitis and Meningoencephalitis with Adoptive Transfer of Third Party CMVpp65 Specific T-Cell Lines (2015) (0)
Non-Hodgkin’s lymphoma (1983) (0)
Fludarabine Based Preparative Regimen Can Secure a Second Hematopoietic Stem Cell Transplant After Initial Graft Rejection (2012) (0)
Empiric Anti-Thymocyte Globulin (ATG) Dosing in Ex-Vivo CD34-Selected Myeloablative Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) May Result in ATG Overexposure That Negatively Affects Outcomes (2018) (0)
Long-Term Survival After T-Cell Depleted Allogeneic Stem Cell Transplantation in Patients With Acute Lymphoblastic Leukemia (2011) (0)
Dual-Sensitized T-Cells Responding to EBV Blcl and Either CMVpp65 or WT-1 Peptide Pools Have Distinct or Shared HLA Restrictions That May Depend on the Presenting HLA Alleles (2018) (0)
A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis (2016) (0)
P-221 Characteristic of relapse after T cell depleted (TCD) allogeneic hematopoietic stem cell transplantation in patients with advanced MDS (2013) (0)
Bone marrow transplantation for myelodysplastic syndromes and secondary acute myelocytic leukemia (1994) (0)
Development and analysis of Wilms’ tumor protein (WT1) specific T cells for adoptive immunotherapy of epithelial ovarian cancer (2005) (0)
Analysis of 129 Myeloablative Double-Unit Cord Blood Transplantation Recipients Demonstrates an Independent Association Between Non-Dominant Unit TNC Dose and Engraftment Suggesting a Facilitation Effect (2014) (0)
Outcomes after Hematopoietic Cell Transplant and Gene Therapy for Adenosine Deaminase (ADA) Severe Combined Immune Deficiency: A Combined Analysis from the Primary Immune Deficiency Treatment Consortium (PIDTC) 6901 and 6902 Studies (2022) (0)
Analysis of 129 Myeloablative Double-Unit Cord Blood Transplantation Recipients Demonstrates an Independent Association Between Non-Dominant Unit TNC Dose and Engraftment Suggesting a Facilitation Effect (2014) (0)
Adoptive Immunotherapy for CMV Infection Complicating Haploidentical Transplants: Challenges Posed by the HLA Restriction of Immuno- Dominant Donor T Cells (2008) (0)
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer (2021) (0)
HLA Genotype Is Associated with Cytomegalovirus Reactivation in Pediatric Allogeneic Hematopoietic Cell Transplant (2021) (0)
The Impact of Individual Co-Morbidities in Myeloablative Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation (2020) (0)
Epstein-Barr virus infections in the oncology patient (2003) (0)
Bone Marrow Mixed Chimerism Is a Risk Factor for Relapse After T-Cell Depleted Allogeneic Stem Cell Transplant (2012) (0)
HLA typing of lymphocyte subpopulations for the identification of intrauterine-derived engrafted maternal cells in patients with severe combined immunodeficiency (SCID) (1982) (0)
Allogeneic bone marrow transplantation (BMT) for the treatment of children with very high risk acute lymphoblastic leukemia (ALL) in first remission (CR1) (2004) (0)
The clinical investigator award--promoting patient-related research. (2001) (0)
tetramers Targeted deletion of T-cell clones using alpha-emitting suicide MHC (2013) (0)
Comparison of Graft Content and Efficiency of T Cell Depletion in Bone Marrow and Peripheral Blood Stem Cells Grafts After Manipulation by Three Negative or Positive CD34+ Selection Strategies (2013) (0)
A Primary Immune Deficiency Treatment Consortium (PIDTC) Study of Chronic and Late Onset Medical Complications after Initial Hematopoietic Cell Transplantation (HCT) for Severe Combined Immunodeficiency Disease (SCID) (2022) (0)
Association of MBL2 genotypes wtih infections and outcome after allogeneic stem cell transplantation (2016) (0)
A Phase I-II Dose Escalation Trial of Clofarabine Plus Melphalan and Thiotepa Followed by Unmodified Allogeneic Stem Cell Transplant (SCT) for the Treatment of High Risk or Advanced Acute Leukemia (2010) (0)
Differential Toxicity Profile of Busulfan and Treosulfan on Endothelial Cells in Vitro—Relevance to Hematopoietic Stem Cell Transplantation (2018) (0)
TherapeuticEfficacyofanFc-EnhancedTCR-likeAntibodyto the Intracellular WT1 Oncoprotein (2014) (0)
#662 Taxol induces wide-spread necrosis in rhabdomyosarcoma (1997) (0)
CMV-specific T-cells following haploidentical transplants: reshaping a repertoire by half. (2022) (0)
Abstract 4978: Adoptively transferred CMV-specific T-cells recognizing dominant and sub-dominant pp65 epitopes demonstrate improvedin vivoinhibition of tumor xenografts in combination with PD-1 inhibition (2017) (0)
Adoptive Therapy and Subdominant Viral Epitopes for Cytotoxic T Cells Specific for Both Dominant Prevalent HLA Alleles Permits Generation of A Panel of Artificial APCs Expressing (2009) (0)
Clinical Outcomes and Salvage Therapies of Pediatric Patients with Progressive B-ALL Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy (2023) (0)
HLA-matched marrow grafts depleted of T cells by lectin agglutination and E-rosette depletion (SBA−E−BMT) in the treatment of leukemia, a report in the first 60 cases (1986) (0)
Comparable Survival with Organ Toxicity Predicting for Overall Survival (OS) and Non-Relapse Mortality (NRM) in Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT) (2017) (0)
Artificial Antigen Presenting Cells Expand NY-ESO-1 Antigen-Specific CD8+ T Cells From Patients with Melanoma (2011) (0)
Graft-Versus-Host Disease (GVHD) After Double-Unit Cord Blood Transplantation (DCBT) Is Associated with Unique Clinical Features Including a Higher Incidence of Grade III-IV Acute GVHD in Children (2011) (0)
Response to Hepatitis B Vaccination Following Allogeneic Hematopoietic Cell Transplantation (HCT). (2005) (0)
Therapeutic Cyclosporine-a (CSA) Levels in the First 7 Days after Cord Blood Transplantation (CBT) Are Critical to Prevent Severe Acute Graft-Versus-Host Disease (aGVHD) (2018) (0)
Allogeneic Hematopoietic Stem Cell Transplantation Of Patients With Wiskott-Aldrich Syndrome With Total Body Irradiation (TBI), Thiotepa and Fludarabine Or Cyclophosphamide Followed By T-Cell Depleted Grafts From Alternative Donors (2013) (0)
Cytotoxic Injury to Thymic Stroma and Impaired Reconstitution. (2004) (0)
Immunosupression for sensitized aplastic anemia patients: Comparison of TLI with TBI (1984) (0)
Host T-Cells Contribute to Immune Reconstitution and Improved Outcome in Recipients of CD34 Selected T-Cell Depleted Allografts (TCD HCT) with Full Hematopoietic Cell but Persistent Mixed T-Cell Chimerism (2020) (0)
Clonal development (MDS) in aplastic anemia (AA) patients with long-term survival (1991) (0)
A Chemotherapy-only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit ATG followed by Allogeneic T-cell Depleted Hematopoietic Stem Cell Transplants for the Treatment of Myeloid Malignancies (2018) (0)
Intrathecal Chemotherapy Post Hematopoietic Cell Transplantation for Prevention of Central Nervous System Relapse in Pediatric Acute Leukemia (2014) (0)
Universal Engraftment after Allogeneic HCT Using Cryopreserved CD34+ Cell-Selected Grafts (2018) (0)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Pediatric Patients with Treatment Related Myelodysplastic Syndrome or Acute Myelogenous Leukemia (tMDS/AML) (2010) (0)
Predictors of Donor/Host (D/H) Lineage Specific Chimerism Trends in Pediatric Patients Following Allogeneic Hematopoietic Cell Transplantation (2019) (0)
agglutinin and sheep red blood cells HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean Transplantation for severe combined immunodeficiency with (2011) (0)
Housing Deadline for Tandem BMT Meetings (2002) (0)
Human Colon Carcinoma Cells Expressing CMVpp65 Antigen: An IN-VIVO Model for Adoptive Immunotherapy Of CMV Disease (2009) (0)
CT7/MAGE-C1 Expression and Immune Responses Following Allogeneic Transplant for Multiple Myeloma (2013) (0)
T-Cell Depleted (TCD) Hematopoietic Stem Cell (HSC) Boosts From the Original Donor without Conditioning for Poor Graft Function (PGF) Following Allogeneic Hematopoietic Stem Cell Transplants (HSCT) (2011) (0)
Persistent or New Cytopenias Are a Better Predictor of Relapse Than Routine Bone Marrow Aspirate Evaluations after Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome in Pediatric and Young Adult Patients (2021) (0)
soybean lectin-separated and E rosette-depleted bone marrow Interleukin 2-activated killer cells in patients following transplants of (2013) (0)
T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HCT) For Adult Patients With Acute Myelogenous Leukemia (AML) In First and Second Remission: Long-Term Disease Free Survival(DFS) With a Significantly Reduced Risk Of Graft-Versus-Host Disease(GvHD) (2013) (0)
Characterization of the tumor-specific activity of WT1 specific T cells generated in vitro from normal individuals by sensitization with WT1-peptide loaded autologous EBV transformed B cells (2004) (0)
Induction of Remission Prior to Transplantation Improves the Disease-Free Survival (DFS) of Patients with Advanced Myelodysplastic Syndromes (MDS) Treated with Myeloablative T-Cell Depleted (TCD) Stem Cell Transplants (SCT) from HLA Identical Siblings. (2005) (0)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for the Treatment of Children with Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) In First Remission (CR1) (2010) (0)
T-Cell Depleted Allografts From Unrelated Donors Confer A Low Risk Of Relapse On Patients With Hematologic Malignancies (2010) (0)
The Disease Risk Index Predicts Outcomes Including Relapse and Survival in CD34-Selected Allogeneic HCT for Acute Leukemia and Myelodysplastic Syndrome (2016) (0)
Final product composition after ex-vivo T-cell reduction: Miltenyi CliniMACS versus Baxter Isolex 300I in a large cohort of allogeneic trans-plant patients (2013) (0)
Outcomes of Two Chemotherapy-Based Preparatory Regimens Compared to TBI-Based Conditioning When Used with CD34+ Selected T-Cell Depleted Allohct for High Risk Hematologic Malignancies: Prospective Clinical Trial NCT 01119066 (2020) (0)
The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles (2023) (0)
T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia and MDS/AML at a Single Institution (2021) (0)
27 A novel strategy for generating LMPI specific T cells utilizing artificial antigen presenting cells (2003) (0)
Quantitation of WT1 Transcripts by Copy Number Provides a Sensitive Indication of Minimal Residual Disease (MRD) and Response to Adoptive Cell Therapy in Patients Transplanted for Ph(+) CML. (2009) (0)
Allo- HSCT for Advanced Myelodysplastic Syndrome:MSKCC Vs MDACC (2014) (0)
Functional T Cells Reactive Towards Tumor-Specific Phosphopeptides Presented By HLA A0301 and A1101 Are Present in Healthy Individuals (2021) (0)
In T-cell lines dually sensitized with antigens from EBV and CMV or from EBV and WT1 the T-cells specific for CMV or WT1 are often restricted by hla alleles that differ from those restricting T-cells specific for EBV (2019) (0)
Standard ATG Dosing Results in Poorer Outcomes in Overexposed Patients after Ex vivo CD34 + Selected Allogeneic Hematopoietic Cell Transplantation (2020) (0)
Adoptive Immunotherapy in the Treatment of Post-Transplant Relapse and Epstein-Barr Virus Lymphoproliferative Disorders (1998) (0)
Baseline Immune Status Predicts Response to Adoptive Therapy with CMV Cytotoxic T-Cells for Refractory CMV (2020) (0)
Aberrant T-cell exhaustion in SCID survivors with poor T-cell reconstitution post transplant. (2022) (0)
A Simplified Comorbidity Index Predicts Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Recipients (2021) (0)
Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer. (2022) (0)
The effects of cytotoxic and immunosuppressive agents on thymic reconstitution (2005) (0)
DNA methylation enzymes and PRC1 restrict B-cell Epstein–Barr virus oncoprotein expression (2020) (0)
Intestinal Microbiota Composition and Diversity Are Associated with CD4 T Cell Reconstitution after Allogeneic Hematopoietic Cell Transplantation (2021) (0)
Generation of CMV specific cytolytic CD4+ and CD8+ T-cells by sensitization with a single pentadecapeptide of CMV pp65 containing both MHC class I and class II epitopes (2005) (0)
Improved Survival in Patients with Refractory Cytopenias (Low Risk Myelodysplastic Syndrome - MDS) Treated with Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants (allo TCD-HSCTs), (2011) (0)
Cancer Therapy: Preclinical TherapeuticEfficacyof anFc-EnhancedTCR-likeAntibody to the Intracellular WT1 Oncoprotein (2014) (0)
Impact of Rabbit Anti-Thymocyte Globulin (rATG) Exposure in Ex Vivo T-Cell Depleted Hematopoietic Cell Transplantation in Children and Young Adults (2023) (0)
Double-Unit Cord Blood (CB) Transplantation (dCBT) Supplemented with Haplo-Identical CD34+ Cells May be Associated with Enhanced Neutrophil Recovery but Successful Myeloid Bridging Is Strongly Influenced By Haplo CD34+ Cell Dose and Haplo-Winning CB Unit HLA-Match (2019) (0)
Do Patients with High Risk or Relapsed Core Binding Factor Acute Myeloid Leukemia Benefit from Salvage Allogeneic Stem Cell Transplantation (2014) (0)
Unrelated Donor T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Advanced Myelodysplastic Syndromes (MDS): The MSKCC Experience (2012) (0)
T- Cell Depleted Peripheral Blood Stem Cell (TCD-PBSC) Transplants Secure Consistent Engraftment with Low Risk of Acute or Chronic Gvhd and Favorable Disease Free Survival (DFS) and Overall Survival (OS) for Pediatric Patients (<21 years) with AML in CR1 (2016) (0)
Myeloablative Double-Unit Cord Blood Transplantation (CBT) in Pediatric Patients with High-Risk Acute Leukemia Demonstrates Encouraging Disease-Free Survival with Both TBI and Chemotherapy-Only-Based Conditioning (2014) (0)
Busulfan, Melphalan, and Thiotepa Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) of Pediatric Patients with Acute Leukemia and Central Nervous System (CNS) Disease (2014) (0)
Injury to the Thymic Niche for DN2/DN3 Developing T Cells Impairs Reconstitution. (2006) (0)
Safety and Effectiveness of Intravenous Palivizumab for Prevention of Respiratory Syncytial Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation (2012) (0)
Damage to Aging Thymic Stroma and De Novo T Cell Development. (2007) (0)
Comparison of two T-cell depletion methods of grafts from alternative donors for allogeneic hematopoietic cell transplantation of patients with fanconi anemia. (2019) (0)
Native and Fc Enhanced Therapeutic Human Monoclonal Antibodies Targeting the Intracellular WT1 Oncogene Product in Leukemia. (2012) (0)
A Novel Chemotherapy-Based Allogeneic Hematopoietic Stem Cell Transplant Regimen for Very Young Children with Leukemia. (2012) (0)
Storage of CD34-positive selected HPC (2014) (0)
Treatment with Banked 3rd Party Donor Derived Virus Specific T Cells: The Advantages of Pre-Defined HLA restriction and Epitope Specificity (2020) (0)
A Comparison of Human CMVpp65-Specific Central Memory and Effector Memory CD8 T-Cells When Stimulated in-Vivo with IL-2 or IL-15/IL-15Rα Complex in a Murine Xenograft Model of Adoptive Cell Therapy (2014) (0)
Adoptive Immune Cell Therapy Using Third Party T-Cell Donors In the Treatment of EBV Related Diseases In Immunodeficient Recipients (2010) (0)
#686 The evaluation of IGF‐1 as a possible promoter for EBV lymphoma in vitro and in vivo (1998) (0)
Paroxysmal Nocturnal Hemoglobinuria (PNH) In Pediatric Patients: Review of a Single Center Series (2010) (0)
Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults (2020) (0)
Combining the disease risk index and hematopoietic cell transplant co‐morbidity index provides a comprehensive prognostic model for CD34+‐selected allogeneic transplantation (2020) (0)
Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL (2019) (0)
130Functional analyses of cytomegalovirus-specific long-term memory effector cells (2003) (0)
Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical CD34+ Selected Peripheral Blood Stem Cells (PBSC) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection and Frequent Pre-Engraftment Syndrome (2014) (0)
B-cell ontogeny depleted bone marrow transplantation: a recapitulation of normal B-cell differentiation following autologous, conventional, or T-cell (2011) (0)
High Disease-Free Survival (DFS) Supports Continued Investigation of Double-Unit Cord Blood Transplantation (DCBT) in Children with High-Risk Acute Leukemia Especially in the Setting of Single Units with Low Dose and/or a High Degree of HLA-Mismatch (2015) (0)
TLR4 Receptor Polymorphisms are Associated with Gram-negative Bacteremia after Allogeneic Stem Cell Transplantation (2008) (0)
Abstract B050: Functional characterization of virus specific stem cell like memory T cells, their maturation in vitro, and potential contribution to secondary T cell responses (2016) (0)
Graft-Versus-Host Disease (GVHD) After Double-Unit Cord Blood Transplantation (DCBT) Is Associated with Unique Clinical Features Including a Higher Incidence of Grade III-IV Acute GVHD (aGVHD) in Children (2012) (0)
Late Effects Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From Alternative Donors In Patients With Fanconi Anemia (FA) (2013) (0)
Population Pharmacokinetic Model Demonstrates Poor Outcomes with ATG Overexposure in Adults Undergoing Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell (2020) (0)
955 TREATMENT OF CHRONIC CYTOMEGALOVIRUS INFECTION WITH INTERFERON (1981) (0)
Autologous mixed lymphocyte reaction in man. XII. Deficiency of the autologous mixed lymphocyte reaction in patients undergoing allogeneic bone marrow transplantation. Relationship with chronic graft-versus-host disease. (1984) (0)
Comparative Analysis of T CELL Depleted Matched Vs Mismatched Unrelated DONOR Transplants in Patients with Hematologic Malignancies (2014) (0)
Comparison of Double Unit Cord Blood Transplants (dCBT) with 8/8 HLA-Allele Matched Related (MRD) or Unrelated Donor (MUD) T-Cell Depleted (TCD) Transplants in Adults with Myeloid Malignancies: Comparable Progression-Free Survival (PFS) (2019) (0)
Myeloprotective Effects of Interleukin-1 Following Exposure to Chemoradiotherapy (1990) (0)
Comparative Effectiveness Analysis Of CD34+Selected, T-Cell Depleted (TCD) HLA-Matched Sibling Grafts On Allogeneic Hematopoietic Cell Transplantation For Patients With Acute Myeloid Leukemia (AML) In Complete Remission (2010) (0)
Incidence, Nature, Risk Factors and Outcomes of Cytomegalovirus Infection After Double-Unit Cord Blood Transplantation (2013) (0)
Rabbit Anti-Thymocyte Globulin (ATG) Exposure after Ex Vivo T-Cell Depleted Hematopoietic Cell Transplantation Is Highly Variable and Impacts Immune Reconstitution in Pediatric and Young Adult Patients (2020) (0)
Human CMVpp65-Specific Stem Cell-like Memory T-Cells (TSCM) Are a Principal Source for Rapid Repopulation of Immunodominant Central Memory (TCM) and Effector Memory (TEM) in the Circulation (2016) (0)
Abstract 5515: WT1 specific T cells can efficiently eliminate tumorigenic ovarian carcinoma cells and prevent or inhibit the tumor growth in NOD/SCID model of ovarian carcinoma (2011) (0)
T Cell Depletion of Allogeneic Human Bone Marrow Grafts by Soybean Lectin Agglutination and Either Sheep Red Blood Cell Rosetting or Adherence on the CD5/CD8 Cellector™ (2020) (0)
Disease-Free Survival in Adult Patients with Acute Leukemia and Advanced CML Supports Use of Double-Unit Cord Blood Grafts As an Immediate Alternative to 8/8 HLA-Matched Unrelated Donors (URD) (2014) (0)
Engrafting Unit-Recipient HLA-Allele Mismatch Is Not Associated with an Increased Risk of Transplant-Related Mortality (TRM) or Inferior Progression-Free Survival (PFS) after Double Unit Cord Blood (CB) Transplantation (dCBT) in Adults with Hematologic Malignancies (2019) (0)
Comparable Survival and Incidence of Toxicity for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation (2016) (0)
Examining cytotoxic effects on thymic reconstitution: a model (2004) (0)
Treatment outcome after induction chemotherapy before allogeneic hematopoietic SCT in patients with advanced MDS. (2006) (0)
An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies (2016) (0)
resistance in human BCR-ABL A TCR-mimic antibody to WT 1 bypasses tyrosine kinase inhibitor (2014) (0)
The Prognostic Significance of Peripheral Blood Mixed Chimerism After T-Cell Depleted Allogeneic Stem Cell Transplant (2013) (0)
Combining the Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Provides a Comprehensive Prognostic Model for CD34-Selected Allogeneic HCT (2017) (0)
In vivo dual modality contemporaneous imaging of different tumor reactive T-cell subpopulations (2005) (0)
Ten allele high-resolution DNA typing has a direct impact on the disease free survival (DFS) in pediatric recipients of T-cell depleted (TCD) unrelated donor (URD) hematopoietic stem cell transplant (HCT) (2004) (0)
Comprehensive Immunology. Vol. 9. Immunology of human infection. II. Viruses and parasites; immunodiagnosis and prevention of infectious diseases. (1982) (0)
Fludarabine-based conditioning secures engraftment of secondary hematopoietic stem cell allografts (HSCT) used to treat graft failure (2005) (0)
Allogenic Hematopoietic Cell Transplantations Are Effective in Patients with p47phox Chronic Granulomatous Disease: A Primary Immune Deficiency Treatment Consortium Study (2023) (0)
The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901 (2013) (0)
Cellular therapies for solid cancer: clinical experience, challenges and future revolution (2020) (0)
CMV Seropositivity and Viremia Drive T-Cell Reconstitution after CD34-Selected Allogeneic HCT (2017) (0)
T cell receptor V beta spectratyping using RT-PCR to monitor reconstitution following T cell depleted allogeneic BMT and the effect of donor leukocyte infusions on T cell repertoire. (1997) (0)
Preclinical Evaluation Of Human Nor-Epinephrine Transporter (hNET)/MIBG Reporter System For Imaging Adoptively Transferred EBV-Specific Cytotoxic T-Lymphocites (2010) (0)
O46 - Gene therapy in CIITA deficient Bara Lymphocyte Syndrome (1996) (0)
Hematopoietic stem cell transplantation for the treatment of fanconi anemia using a fludarabine-based cytoreductive regimen and T-cell depleted grafts from alternative donors (2004) (0)
Comparison of T Cell Subset Recovery after Cord Blood and CD34-Selected Pbsc Transplantation (2018) (0)
Phase I/II trial of Arginine Butyrate and ganciclovir in Epstein-Barr virus-associated lymphoid malignancies. (2006) (0)
Spontaneous and concanavalin A induced suppressor cell activity in patients undergoing bone marrow transplantation: relationship with acute and chronic graft versus host disease. (1983) (0)
Generation of CMV-Specific T-Lymphocytes for Adoptive Immunotherapy: A Comparison of Artificial Antigen-Presenting Cells and Autologous Dendritic Cells Pulsed with CMV-pp65 Protein-Spanning Pentadecapeptide Pools. (2005) (0)
Author Correction: DNA methylation enzymes and PRC1 restrict B-cell Epstein–Barr virus oncoprotein expression (2022) (0)
#633 HLA‐DQBI disparity between patients and unrelated marrow donors (URD) matched for HLA‐A, B, and -DRBI by DNA typing (1998) (0)
Epstein-Barr virus-specific cytotoxic T lymphocyte precursors (EBV-CTLp) after tabelecleucel correlates with response & survival in rituximab relapsing or refractory EBV posttransplant lymphoproliferative disease (PTLD) (2020) (0)
#632 HLA‐C disparity between patients and unrelated donors (URD) matched for HLA‐A, -B, and -DRVI alleles by DNA typing (1998) (0)
hematopoietic and microenvironmental elements of human bone marrow Effects of in vitro purging with 4-hydroperoxycyclophosphamide on the (2011) (0)
transplantation and donor lymphocyte infusions depleted hematopoietic stem cell − undergoing allogeneic T cell WT 1-specific T-cell responses in high-risk multiple myeloma patients (2013) (0)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Non Malignant Hematologic Disorders (NMHD), Using a Chemotherapy-Only Cytoreductive Regimen and T-Cell Depleted Grafts from Alternative Donors (2014) (0)
Absolute Lymphocyte Count At Day 30 Predicts Survival In Recipients Of A T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (2009) (0)
Allogeneic or Autologous Stem Cell Transplantation (SCT) for the Treatment of Pediatric Patients with Non-Hodgkins Lymphoma (NHL). (2005) (0)
Differences in the phenotype and in vivo anti-tumor activity of WT1 specific and EBV-specific T-cells generated in vitro for adoptive immunotherapy (2006) (0)
Imaging , Diagnosis , Prognosis KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma (2009) (0)
Results of T Cell Depleted (TCD) Myeloablative Hematopoietic Stem Cell Transplants (HSCT) in Patients with Hematologic Malignancies ≥ 55 yrs of Age. (2005) (0)
Abstract A055: Potent therapeutic and immunological effects of the first T-BiTE derived from a TCR-mimic antibody targeting intracellular oncoprotein WT1 (2016) (0)
Anti-Thymocyte Globulin Exposure in CD34+T Cell Depleted Allogeneic Hematopoietic Cell Transplantation (2021) (0)
Dose-Dependent and Epitope-Specific in Vivo Irradication of the Human Ovarian Carcinoma Cells Expressing the Willms Tumor Protein, WT1, in NOD/SCID Mice, by WT1 Specific T Cells Monitored by Bioluminescent Imaging (2011) (0)
Treatment of the immunodeficiency diseases — progress toward replacement therapy emphasizing cellular and macromolecular engineering (1978) (0)
Comprehensive Immunology, Vol. 8. Immunology of human infection. I. Bacteria, mycoplas-mae, chlamydiae, and fungi. (1981) (0)
Retrospective Analysis of Standard Versus Mini-Dose Methotrexate in the Prevention of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplant Recipients (2012) (0)
The effect of donor leukocyte infusions on development of EBV specific immunity post-marrow transplantation (1994) (0)
Proceedings/ Host-graft interactions in allogeneic bone marrow transplantation, symposium, Tucker's Town, Bermuda, June 25-27, 1987 (1987) (0)
954 HUMORAL IMMUNE RESPONSE IN VITRO AFTER BONE MARROW TRANSPLANTATION (BMT) (1981) (0)
Second Allogeneic Stem Cell Transplantation for Hematologic Malignancies Using Chemotherapy Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa (2014) (0)
Long-Term Follow-Up of Adult Double Unit Cord Blood (CB) Transplantation (dCBT) Recipients Reveals High Rates of Progression-Free Survival after a Novel Cy/ Flu/ Thio/ TBI 400 Intermediate Intensity Conditioning Regimen (2017) (0)
High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL (2017) (0)
Event Free Survival in Severe Combined Immune Deficiency (SCID) Infants after Conditioned Umbilical Cord Blood Transplantation (UCBT) Benefits from Omitting Serotherapy (2023) (0)

This paper list is powered by the following services:

Richard J. O’reilly's Academic­Influence.com Rankings

Richard J. O’reilly's Degrees

Why Is Richard J. O’reilly Influential?

Richard J. O’reilly's Published Works

Published Works

Richard J. O’reilly's AcademicInfluence.com Rankings